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Parvovirus B19 is the causative agent of “fifth disease” of childhood. It has been implicated in a variety of
conditions, including unsuccessful pregnancy and rheumatoid arthritis, and is a potential contaminant of
blood products. There has been little study of immunity to parvovirus B19, and the exact nature of the
protective humoral and cell-mediated immune response is unclear. Immune responses to purified virus capsid
proteins, VP1 and VP2, were examined from a cohort of recently infected children and compared with
responses from long-term convalescent volunteers. The results demonstrate that antibody reactivity is pri-
marily maintained against conformational epitopes in VP1 and VP2. The unique region of VP1 appears to be
a major target for cell-mediated immune responses, particularly in recently infected individuals. We confirm
that antibody reactivity against linear epitopes of VP2 is lost shortly after infection but find no evidence of the
proposed phenotypic switch in either the subclass of parvovirus B19-specific antibody or the pattern of cytokine
production by antigen-specific T cells. The dominant subclass of specific antibody detected from both children
and adults was immunoglobulin G1. No evidence was found for interleukin 4 (IL-4) or IL-5 production by
isolated lymphocytes from children or adults. In contrast, lymphocytes from convalescent adults produced a
typical type 1 response associated with high levels of IL-2 and gamma interferon (IFN-g). However, we
observed a significant (P < 0.001) deficit in the production of IFN-g in response to VP1 or VP2 from
lymphocytes isolated from children. Taken together, these results imply that future parvovirus B19 vaccines
designed for children will require the use of conformationally preserved capsid proteins incorporating Th1
driving adjuvants. Furthermore, these data suggest novel mechanisms whereby parvovirus B19 infection may
contribute to rheumatoid arthritis and unsuccessful pregnancy.
Human parvovirus B19 (B19V) causes the common child-
hood illness known as “fifth disease” or erythema infectiosum.
While the symptoms are generally mild, there are a variety of
conditions under which infection has more severe outcomes. In
the immunocompromised or patients with underlying hemo-
lytic disorders, such as sickle-cell disease and hereditary sphe-
rocytosis, infection with B19V can result in an acute aplastic
crisis or in chronic anemia (39, 53). During pregnancy, the
virus can be transmitted transplacentally from an infected
mother to the fetus and can cause spontaneous abortion or
fetal anemia (9). Direct infection of the fetus can result in
nonimmune hydrops fetalis. B19V has also been linked to
arthritis in adults and children (41). It has been estimated that
60% of women with symptomatic disease manifest arthropathy
(53). The symptoms generally subside within 3 weeks, but
about 20% of affected women suffer a persistent or recurring
arthropathy. At present there is no effective vaccine available
either for women of child-bearing age or for the general pop-
ulation.
B19V is a small, nonenveloped, single-stranded DNA virus
classified as an erythrovirus. The virus replicates in human
erythroid progenitor cells of the bone marrow and blood, in-
hibiting erythropoiesis (54). Infection with B19V is common,
and upwards of 60 to 70% of the population is seropositive by
adulthood (8). Transmission most commonly occurs by per-
sonal contact via aerosol or respiratory secretions; however,
contaminated blood products may also be a source of iatro-
genic transmission.
The B19V capsid consists of an 83-kDa minor structural
protein, VP1, and a 53-kDa major structural protein, VP2. VP2
makes up about 95% of the total capsid, with VP1 making up
the remainder (38). The sequences of the two proteins are
colinear, with VP2 being identical to the carboxyl terminus of
VP1; however, VP1 contains an additional 227 amino acids
unique to the amino-terminal end.
Although little is known about the protective immune re-
sponse against B19V in humans, specific antiviral antibody is
considered the major mechanism of protection. This is based
on the circumstantial evidence that high-dose immunoglobulin
therapy is sometimes beneficial for infected patients (23, 43).
This treatment does not work in all cases, and no data is
available on the actual protective level of B19V immunoglob-
ulin G (IgG), although levels greater than 6 IU are thought to
be protective (44). It has been previously shown that a time-
dependent change in antibody response occurs against viral
capsid proteins by an unknown mechanism (47). It is charac-
terized by a loss of antibody specificity against linear viral
epitopes of VP1 and VP2 and also by a proposed antibody
subclass switch from IgG3 to IgG4. It has been speculated that
this switch is caused by an underlying alteration in the type of
CD41 T-cell response; however, there has been very little
examination of this response in humans (16, 51). It is accepted
that in response to antigen, T helper (Th) cells secrete cyto-
kines, which are involved in regulatory functions or can medi-
ate direct activity against invading viruses. The current para-
digm is that Th cells can be subdivided into at least three
populations according to the pattern of cytokines secreted on
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activation. Th1 cells secrete interleukin 2 (IL-2), gamma inter-
feron (IFN-g), and tumor necrosis factor beta, Th2 cells se-
crete IL-4 and IL-5 (34), and the recently described regulatory
subset (Tr1) produces IL-10 (1, 13, 33, 40). The Th cell subset
classification also correlates with a functional dichotomy. Th1
cells are the principal effectors of proinflammatory reactions,
delayed-type hypersensitivity, and cell-mediated immunity
against intracellular pathogens. The main Th1 cytokine, IFN-g,
enhances the differentiation of CD81 T lymphocytes into ac-
tivated cytotoxic T leukocytes, activates macrophages to phago-
cytose and destroy microbial pathogens, and has a direct anti-
viral effect (30, 49). The precise natures of the protective
humoral and cell-mediated responses to B19V are unknown,
but such understanding is central to the rational design of a
protective vaccine and will also influence the choice of a vac-
cine delivery vehicle.
In the present study, we provide the first systematic exami-
nation of the humoral and cell-mediated immune responses
from cohorts of recently infected children and from seroposi-
tive and seronegative adult volunteers. This study provides the
first characterization of the patterns of antigen-specific cyto-
kine induction in this infection and correlates these responses
with an analysis of the subclass of antigen-specific antibody
induced in children and adults. The data challenge the exis-
tence of a Th1-to-Th2 phenotypic switch following B19V in-
fection but demonstrate a deficient IFN-g response to the virus
in recently infected children.
MATERIALS AND METHODS
Patients. Heparinized blood samples (n 5 19) were obtained 3 months after a
confirmed outbreak of B19V infection at a national school from children be-
tween ages 7 and 11 who had displayed symptoms of fifth disease. These samples
were labelled A1 to A19. Blood samples were also taken from a panel of healthy
adult volunteers with no recent record of B19V or other infection (n 5 26).
These samples were identified numerically with a prefix of “B” or “V.” Samples
that tested positive from this cohort of adults are considered to indicate past
infection and are referred to as “convalescent” in the text. Consent was obtained
from all volunteers or their guardians prior to sample collection.
Antigens. B19V recombinant VP1 and VP2 proteins were expressed in the
baculovirus expression system using Spodoptera frugiperda (Sf9) insect cells (6, 7).
VP1 was prepared by detergent lysis of recombinant cells, removal of soluble
protein by centrifugation, and solubilization by 6 M guanidinium chloride. VP2
was purified by lysing recombinant cells and precipitating the protein with am-
monium sulphate using a modification of previously described methods (12).
Purity was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and Western blot analysis. Both preparations were dialyzed into 50 mM carbon-
ate buffer, pH 9.6, and the pH was neutralized before use in T-cell proliferation
and cytokine production assays. For determinations of IgG reactivity by enzyme
immunoassay (EIA) against nonconformational or linear epitopes, VP1 and VP2
preparations were linearized with 5 mM dithiothreitol–0.1% (wt/vol) sodium
dodecyl sulfate prior to microplate coating. Antigens were stored at 220°C until
use.
Antibody assays. Plasma obtained from blood samples was used to examine
the B19V IgG reactivity to the capsid proteins. Total B19V-specific IgG for
conformational VP2 (VP2-N) was determined by commercial EIA (Biotrin In-
ternational, Dublin, Ireland). Linear VP1 (VP1-D) and VP2 (VP2-D) were also
determined by EIA. Briefly, microtiter plates (Nalge Nunc International, Ro-
skilde, Denmark) were coated overnight at 4°C with either VP1-D or VP2-D.
Plates were washed and then blocked for 2 h before incubation for 1 h at 20°C
with plasma samples, diluted in 0.05% (wt/vol) Tween 20–phosphate-buffered
saline. After four washes, wells were treated with horseradish peroxidase-conju-
gated anti-human IgG (Dako A/S, Glostrup, Denmark) for 30 min. After further
washing, this complex was detected by the addition of tetramethyl benzidine
substrate for 10 min. The reaction was terminated with the addition of 1 N
sulfuric acid. Absorbance was measured at 450 and 630 nm. Results are ex-
pressed as index values (I.V.) representing specimen absorbance divided by
cutoff absorbance. The cutoff was established as the absorbance 2 standard
deviations greater than the mean absorbance obtained from a panel of B19V-
negative samples. An I.V. of less than 1.0 was considered seronegative. VP2-N
EIA reactivity was calibrated against the international standard for B19V-spe-
cific antibody (15). IgG reactivity to conformationally intact VP1 (VP1-N) was
determined by a commercial qualitative immunofluorescent assay. The degree of
fluorescence was graded on a scale of 0 to 4 according to the manufacturer’s
instructions (Biotrin International).
IgG subclass assays. Microtiter plates were coated with VP1 and VP2 and
incubated with plasma samples as described for total B19V IgG EIA. IgG
subclasses were detected by incubation at 20°C for 1 h with murine monoclonal
antibodies specific for human IgG1, IgG2, IgG3, or IgG4 (Serotec, Ltd., Oxford,
United Kingdom). Following a wash step, horseradish peroxidase-conjugated
anti-mouse IgG (Bio-Rad Laboratories, Hertfordshire, United Kingdom) was
added to wells. The complex was then detected by addition of tetramethyl
benzidine substrate and terminated by adding 1 N sulfuric acid. The absorbance
was measured at 450 and 630 nm. I.V. were calculated as before.
T-cell proliferation assay. Peripheral blood mononuclear cells (PBMC) from
adults or children were isolated by density gradient centrifugation as previously
described (42). PBMC (2 3 106 cells/ml) were cultured in triplicate with purified
recombinant VP1 (10 mg/ml) or VP2 (10 mg/ml) for 72 h. Cells cultured with
medium alone or with a combination of phytohemagglutinin (PHA) (2 mg/ml)
served as negative and positive controls, respectively. For the final 4 h of culture,
cells were labeled with 1 mCi of [3H]thymidine before harvesting as previously
described (42). Background values for negative control samples were typically
between 200 and 600 cpm and always less than 1,500 cpm. Results are expressed
as stimulation indices (S.I.), representing the proliferative response for test
samples divided by the response obtained from the negative control sample.
Analysis of cytokine production. Supernatants were removed from PBMC
cultures after 24 h to determine the concentration of IL-2 and after 72 h to
determine the IFN-g, IL-4, and IL-5 concentrations as previously described (42).
Briefly, IL-2 release was assessed by the ability of culture supernatants to support
the proliferation of the IL-2-dependent cell line CTLL-2. Concentrations of IL-4,
IL-5, and IFN-g were determined by EIA using commercially available antibod-
ies (PharMingen, San Diego, Calif.). Concentrations were determined by com-
paring either the proliferation or the absorbance at 405 nm for test samples with
a standard curve for recombinant cytokines of a known potency and concentra-
tion.
Statistical methods. Cytokine secretion data from different treatment groups
were compared by use of the Student t test.
RESULTS
Antibodies against conformational epitopes of VP1 and VP2
persist, and those against nonconformational determinants
are lost. Previous serological studies have suggested that anti-
body responses against linear, but not conformational, epi-
topes of the B19V capsid protein VP2 are lost during conva-
lescence. If correct, these findings have serious implications for
peptide-based vaccines. In the present study, we examined this
phenomenon using individual samples in well-characterized,
standardized assay systems. A strong antibody response against
B19V was observed in 16 of 19 specimens taken from children
within either 3 months of infection or 3 months of presentation
with symptoms of infection (Fig. 1A). The humoral response
against B19V in this cohort of recently infected children is
dominated by the presence of antibodies directed against con-
formational epitopes on VP1 and VP2 and against linear
epitopes present on the unique region of VP1. Specifically, all
16 seropositive children exhibited intense immunoreactivity
against epitopes on conformationally intact VP1-N and linear-
ized VP1-D (mean I.V. 5 7.14 6 2.6) (Fig. 1C). Samples from
these children also displayed .100 IU of B19V IgG/ml di-
rected against VP2-N (Fig. 1E). The observed reactivity
against VP2-D (mean I.V. 5 1.67 6 0.7) (Fig. 1G) confirms
both the poor immunogenicity of linear epitopes present in
VP2 and that the observed immunoreactivity with VP1-D is
indeed directed against the 227-amino-acid VP1-unique re-
gion. No viral DNA was found in any specimen tested (data not
shown), and all children made a full recovery from B19V
infection.
The antibody response against B19V capsid antigens was
also determined from a panel of either seronegative (n 5 8) or
long-term convalescent, seropositive (n 5 18) volunteer do-
nors. There is a persistence of antibody reactivity directed
against conformational epitopes on VP1-N and VP2-N (mean
amount of B19V IgG 5 91.8 6 63 I.U./ml) (Fig. 1B and F).
However, the data also illustrate a significant loss of immuno-
reactivity against VP1-D (mean I.V. 5 1.73 6 2.36) (Fig. 1D)
compared to that for recently infected individuals (P 5 0.001).
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Indeed, 11 of 18 (61%) exhibited no immunoreactivity against
linear epitopes on the VP1-unique region even in the presence
of significant reactivity against VP1-N and VP2-N. The ex-
pected minimal immunoreactivity against VP2-D was observed
(Fig. 1H) (mean I.V. 5 1.2 6 1.7). This value was not signif-
icantly different from values for the antibody response against
VP2-D in recently infected children (P 5 0.306). Thus, the
antibody response generated by infection against linear or non-
conformational epitopes of B19V does not persist with time.
The humoral response against B19V is dominated by IgG1.
The subclasses of B19V-specific antibody from recently in-
fected children or convalescent adults were measured to ex-
amine the possibility of an IgG subclass switch in the response
against this virus with time. In the group of 16 B19V IgG-
positive samples from recently infected children (Fig. 2A), the
specific response against VP1-D was dominated by IgG1
(mean I.V. 5 23.5 6 8.7). The observed levels of IgG2, IgG3,
and IgG4 were 1.37 6 0.5, 1.3 6 0.37, and 1.2 6 0.29, respec-
tively. No significant difference was observed between the IgG3
and IgG4 subclass reactivities in this group. Little reactivity of
any antibody subclass was detected against VP1-D in plasma
from convalescent volunteers (Fig. 2B), confirming the loss of
antibody reactivity against nonconformational epitopes that
was previously observed (Fig. 1B). Only three samples (B3, B4,
and B6) showed any reactivity to the denatured capsid antigen,
and these corresponded to patients with the strongest total
B19V IgG response against VP1-D.
The subclass profile of the antibody response directed
against VP2-N was also examined for recently infected chil-
dren and convalescent adults. In both groups, IgG1 dominated
the subclass profile (Fig. 3). Recently infected children showed
a strong IgG2 response (3.5 6 2.4), which was not detected in
long-term convalescent samples. Children’s samples also dis-
played significantly greater levels of IgG3 than IgG4 directed
against VP2-N (P 5 0.001). However, no statistically significant
difference was observed between IgG3 and IgG4 subclass re-
activities for convalescent individuals (P 5 0.1), nor was any
evidence found for a subclass switch in reactivity in this group.
As with VP1-D, the IgG subclass reactivity against VP2-D
was negligible for the majority of specimens tested from either
recently infected children or convalescent adults (Fig. 4 and
data not shown). Only one sample from a recently infected
child, A15 (IgG4 I.V. 5 4.9), and two samples from seropos-
itive adults, B4 (IgG3 I.V. 5 2.4) and B6 (IgG1 I.V. 5 28),
showed any reactivity against VP2 in this form (Fig. 4). The
presence of detectable IgG4 in specimen A15 not only con-
FIG. 1. Total B19V IgG reactivity against VP1 and VP2 in plasma from recently infected children (A, C, E, and G) or previously infected (convalescent) adults (B,
D, F, and H). Results shown are the responses against conformationally intact VP1-N (hatched bars) determined by immunofluorescence assay and graded according
to the manufacturer’s criteria (0, negative; 1, weak positive; 2, intermediate positive; 3 to 4, strong positive) (A and B), against linearized VP1-D (solid bars) determined
by EIA and expressed as I.V. (C and D), against conformational VP2-N (open bars) determined by EIA and expressed as international units per milliliter (E and F),
and against linearized VP2-D (horizontal bars) determined by EIA and expressed as I.V. (G and H).
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firms the functionality of the IgG4 immunoassay but cautions
against the use of pooled serum samples for interpreting the
IgG subclass responses from different cohorts of patients.
VP1 is a major antigenic target for T cells from recently
infected children. There has been little study of the T-cell
response induced by B19V infection in humans. Although all
children included in the present study had displayed clinical
symptoms of infection, three of the samples showed no prolif-
erative T-cell response against VP1 and little or no response to
VP2 (Fig. 5). These three samples were also negative for IgG
and IgM against the capsid proteins VP1 and VP2 (Fig. 1A and
data not shown). The remaining children tested all showed a
specific proliferative T-cell response against VP1, and T cells in
samples from most children also recognized VP2 (Fig. 5 and
data not shown). Since CD41 T cells recognize short linear
peptide sequences and since VP1 and VP2 are colinear, this
suggests that the T-cell response is targeted against at least one
site in the unique region of VP1 corresponding to the 227
amino acids of the unique region of VP1. However, further
T-cell epitopes exist outside this region. This is suggested by
the observed proliferative responses to VP2 by lymphocytes
from seropositive children and adults (Fig. 5 and data not
shown).
Children fail to mount an IFN-g response against B19V. A
switch in the profile of cytokine production by B19V-specific T
cells has been suggested to explain some of the features of
B19V infection in humans. To examine this hypothesis, the
production of the type 1 cytokines IFN-g and IL-2 or the type
2 cytokines IL-4 and IL-5 was examined. Lymphocytes isolated
from recently infected children or from adults seropositive for
B19V did not secrete IL-4 or IL-5 following antigen stimula-
tion (Fig. 6 and data not shown). This strongly suggests that
there is no switch to a Th2 pattern of cytokine expression
during convalescence from B19V infection. In fact, seroposi-
tive adults displayed a potent Th1 response, with high levels of
IFN-g (Table 1) and IL-2 (mean 6 the standard error (SE) 5
0.25 6 0.1 U/ml for VP1 stimulation; 0.43 6 0.01 U/ml for VP2
stimulation). Lymphocytes from recently infected children also
produced IL-2 following VP1 stimulation (mean 6 SE 5
0.12 6 0.05 U/ml) relative to seronegative children (mean 6
SE 5 0.037 6 0.005 U/ml) (Fig. 6). In contrast, antigen-specific
IFN-g production could not be detected from T cells of these
children when stimulated with either VP1 or VP2, despite
strong T-cell proliferative responses (Table 1). This result was
significantly different (P , 0.001) from the strong IFN-g re-
sponses seen from lymphocytes isolated from seropositive
adults that had been stimulated with either VP1 or VP2. No-
tably, mitogen-stimulated controls gave detectable levels of
IFN-g, indicating that this was not due to an intrinsic deficit in
this population.
DISCUSSION
The present study provides the first comprehensive analysis
of both humoral and cell-mediated immunity against B19V
infection in humans. The data show the necessity of determin-
ing IgG reactivity against B19V VP2 to confirm past infection
and the extent of antibody loss against B19V VP1 and VP2
linear epitopes and illustrates that the unique sequence of the
capsid protein VP1 is a major target of the cell-mediated im-
mune response. Analysis of the pattern of cytokine production
following antigen stimulation of lymphocytes from recently
infected children and convalescent adults shows no evidence of
a Th1-to-Th2 switch; likewise, no alteration in the profile of the
antibody subclass was detected. However, our results do show
that recently infected children fail to mount an IFN-g response
FIG. 2. B19V IgG subclass reactivity against linearized VP1 (VP1-D). The results were determined by EIA for B19V-specific IgG1 (solid bars), IgG2 (open bars),
IgG3 (diagonal shading), and IgG4 (horizontal shading). Results are plotted as I.V. for recently infected children (A) and convalescent adults and uninfected
volunteers (B).
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to this virus. This immunological deficit has implications for
the pathology of the childhood infection and for the design of
future vaccines.
Little is known about the nature of the antibody or cellular
response against recent B19V infection in children. Our anal-
ysis of B19V serology in the recently infected children demon-
strates that levels of capsid-specific VP2 IgG exceed 100 IU/ml
within 3 months of infection and that high levels of VP1 IgG
reactivity are also attained in this time period. A number of
recent reports have shown that these antibody responses
against conformational epitopes on VP1 and VP2 persist fol-
lowing B19V infection, whereas humoral responses directed
against linear epitopes of both VP1 and VP2 are lost (21, 47).
Although we observed a similar phenomenon, our results in-
dicate that 61% of convalescent specimens may lack antibodies
directed against linear epitopes on the VP1-unique region.
This finding not only means that B19V diagnostics which do
not contain conformationally intact capsid epitopes may be
unreliable but also has serious implications for vaccine design.
The data suggest that vaccines based on short peptide se-
quences corresponding to regions of the capsid proteins may
not induce a protective or persistent immunological memory.
This is consistent with previous work from different viral sys-
tems demonstrating the importance of conformational anti-
genic determinants in protective immunity (20, 29).
A variety of mechanisms have been invoked to explain why
reactivity against linear epitopes is lost, including the induction
of T-cell anergy or tolerance (16). However, these mechanisms
do not adequately explain why there is a selective loss of
reactivity against the linear epitopes of the capsid proteins. A
more likely explanation centers on the induction of B-cell
memory. B-cell memory is maintained by the persistence of
antigen on specialized follicular dendritic cells. This involves
the deposition of antigen as immune complexes on the surface
of the follicular dendritic cells, a process that preserves the
conformational integrity of the antigen (11, 35, 48). We pro-
pose that this competitive situation would favor the more avid
recognition by B cells expressing surface Ig directed against
conserved conformational epitopes, and hence antibodies
against linear epitopes would tend to be lost from the reper-
toire.
Franssila et al. also reported that there is a subclass switch
for antibody against the VP1-unique region from IgG3 during
acute infection to IgG4 during convalescence and proposed
that this was due to a switch from a Th1 response to a Th2
response (16). In other infections and model systems, members
of our group and others have reported a broadening of cyto-
kine responses with time (2, 3, 27). These have involved initial
responses dominated by either type 1 or type 2 cytokines and
have been due to a variety of factors, including subclinical
FIG. 3. B19V IgG subclass reactivity against VP2-N. The results were determined by EIA for B19V-specific IgG1 (solid bars), IgG2 (open bars), IgG3 (diagonal
shading), and IgG4 (horizontal shading). Results are plotted as I.V. for recently infected children (A) and convalescent adults and uninfected volunteers (B).
FIG. 4. B19V IgG subclass reactivity against VP2-D. The results were deter-
mined by a specific EIA for B19V-specific IgG1 (solid bars), IgG2 (open bars),
IgG3 (diagonal shading), and IgG4 (horizontal shading) only for samples with a
high level of total IgG reactivity against linear VP2. Results are expressed as I.V.
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repeat infection and variables in the initial priming (2, 3, 27).
However, in the present study, we found no evidence of a
switch in either the humoral or cell-mediated immune com-
partments. Although it is possible that a phenotypic switch in
reactive antibody or the pattern of cytokine production may
have occurred prior to 3 months postinfection, previous work
has suggested that this did not occur until at least 3 to 4 months
postinfection (16). Furthermore, the absence of the IgG4 sub-
class in all children’s specimens suggests that it is unlikely that
a previous phenotypic switch has occurred. The dominant sub-
class of antibody specific for B19V detected from recently
infected children or long-term convalescent adults was IgG1.
IgG1 and IgG3 are associated with Th1 responses in humans,
and the lack of specific IgG1 is a feature of parasite-driven Th2
responses (22, 36). The high levels of B19V-specific IgG1 in
convalescent plasma detected in this study are not consistent
with a switch to a Th2 response. Significant levels of IgG3 were
detected in samples from recently infected children in this
study. This is consistent with a recent study by Bostic et al. (5)
and with the well-documented significance of opsonizing and
complement-fixing IgG3 in providing protection against other
viral infections (4, 18, 19, 46). The IgG2 response following
B19V infection appears to be directed mainly against nonlin-
ear epitopes on VP2 and to decline with time. The mechanisms
governing IgG2 induction are thought to involve a factor other
than IFN-g (45), although the reasons for the decline observed
in this study are not clear. IgG4 is the human IgG subclass
most closely associated with Th2-driven immune responses
(14, 22, 36); however, with one exception, little or no B19V-
specific IgG4 was detected for either children or adults.
The elucidation of the protective immune response to B19V
is a prerequisite to the design of an effective vaccine. Initial
efforts to explore the nature of the cellular immune response to
B19V were unsuccessful (24). However, more recent attempts
at studying T-cell proliferation using recombinant B19V anti-
gens have proved more informative (50). The present study
allowed the comparison of specimens taken from individuals
with clinical as well as serological evidence of recent B19V
infection. T cells from recently infected children proliferated
strongly in response to VP1 (Fig. 5). Since the responses to
VP2 were weaker, this suggests that the unique region of VP1,
corresponding to the 227 amino acids at the amino-terminal
end, is a major but not exclusive target for T-cell recognition
and antibody responses generated by infection. This hypothesis
could be addressed by using peptides corresponding to regions
of VP1 and VP2 to map the T-cell epitopes of B19V (28). The
relationship between sites of B-cell recognition and T-cell rec-
ognition on complex antigens is not straightforward; neverthe-
less, our observation for children that these sites reside in close
proximity on the B19V capsid is in accordance with previous
studies. We have previously shown that in poliovirus, there is a
proximity between neutralizing antibody sites 1 and 3 and
sequences recognized by T cells (17, 25, 28), suggesting that
specific antibody may protect adjacent T-cell epitopes during
antigen processing. Proliferative responses by T cells from
adults were generally weaker than those observed in children,
probably reflecting a waning in immunity since infection. In
accordance with the results of von Poblotzki et al., significant
proliferative responses against both VP1 and VP2 were de-
tected in seropositive adult samples (50). It is not clear why the
proliferative response should broaden with time, but this may
represent subclinical exposure to B19V.
Although enhanced IL-1b, IL-6, and IFN-g mRNA produc-
tion has been observed during acute B19V infection in a single
patient (51), there has been no characterization to date of the
pattern of cytokine induction following B19V infection in hu-
mans. In the present study, we found no evidence of the pro-
posed Th2 response to purified B19V antigens in long-term
convalescent subjects; rather, the response in these adult vol-
unteers was dominated by IL-2 and IFN-g, which is typical of
FIG. 5. Proliferative responses of PBMC from children recently infected with B19V. Cells were stimulated in vitro with purified VP1 (horizontal shading), VP2
(solid bars), or either medium alone (open bar) or PHA (diagonal shading) as a negative or positive control, respectively. Results are given as the S.I. and are the mean
(6 the SE) of at least two experiments performed in triplicate. For clarity the results for some positive controls have been truncated at an S.I. of 20.
TABLE 1. IFN-g secretion by PBMC from recently infected
children or adults in response to B19V capsid proteins
Source of
samples
B19V-specific IFN-g productiona
(pg/ml [mean 6 SE]) in response to: No. of
samples
VP1 VP2
Children ,80 ,80 16
Adults 610 6 348 1,765 6 825 7
a IFN-g responses by PBMC isolated from recently infected children or B19V-
seropositive convalescent adults following in vitro stimulation with either puri-
fied VP1 or VP2 (10 mg/ml).
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the Th1 responses induced by many viral infections (28, 29).
Th1 responses have well-documented roles in antiviral immu-
nity; however, such responses are not always beneficial. The
pathological damage witnessed during rheumatoid arthritis is
also associated with type 1 responses. Interestingly, B19V in-
fection has recently been linked to both rheumatoid and juve-
nile arthritis. Another condition in which type 1 responses are
considered detrimental is pregnancy. Pregnancy is associated
with a profound suppression of Th1-mediated immunity (52).
This is thought to protect the fetus from maternal mechanisms
of allograft rejection. Infection of pregnant mothers by B19V is
a well-documented abortifacient (9). Undoubtedly, many of
these cases are due to direct infection of the fetus or to non-
immune mechanisms; however, our data suggest that infection
of immunologically naı¨ve, pregnant women by B19V would
induce a virus-specific Th1 response. This type of response may
not be compatible with carriage of the fetus to term and may
contribute to a B19V-induced immune-mediated fetal loss.
Although we found no evidence of a Th1-to-Th2 switch
following B19V infection, we did observe a significant deficit in
the IFN-g response against capsid proteins in recently infected
children. It has been previously shown that production of
IFN-g by neonatal CD41 and CD81 T cells is markedly lower
than that by analogous adult cell populations (26). This is
supported by studies of primary herpes simplex virus infection,
with which there is a significantly reduced IFN-g response by T
cells from infants compared to that of cells from adults in the
first 3 to 6 weeks postinfection (10). However, other data show
that under certain conditions, neonates and infants can display
a memory Th1-type response of a magnitude similar to that
observed later in life (32). Our data show that the deficit in
IFN-g production is not an intrinsic feature of the T-cell pop-
ulation from recently infected children, since mitogen-specific
responses are equivalent to those seen in adults. It may be that
other deficiencies, either in the antigen-presenting cell popu-
lations or in expression of costimulatory signals, contribute to
this deficit (37).
Whatever the mechanism underlying the antigen-specific
deficit in IFN-g responses observed from these children, our
data have important implications for the design of vaccines
against B19V. It may be that candidate B19V vaccines, de-
signed for childhood immunization, will need to be formulated
with adjuvants or delivery vehicles which favor the induction of
Th1 responses, such as IL-12 or the mycobacterium-derived
trehalose dimycolate, rather than traditional adjuvants, such as
aluminium salts, which tend to induce Th2-type responses (31).
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